Mar. 9 at 2:45 PM
Jefferies reiterated
$DYN Buy/
$50, and said that it Remains 70-80%+ Confident in an AA Approval by 1Q27.
$PEPG $RNA ARWR SNY
$CAPR $EWTX PTCT SRPT
Here's what Jefferies had to say in its note:
At MDA (Mar 8-11):
(1) In DM1 (
$3B+ oppty), z-basivarsen (ASO) starts a confirmatory Phase III trial designed to convert an AA accelerated approval (based on pivotal Phase II results in Q1:27) into a full approval.
(2) In DMD Exon 51 (
$500M+ oppty), z-rostudirsen (PMO) shares new 24-month cardiopulmonary function data from the Phase I/II OLE extension.
We remain 70-80%+ confident in an AA approval by Q1:27, due to recent best-in-class pivotal Phase II data.
